Ptc Therapeutics (PTCT) Operating Income (2016 - 2025)
Historic Operating Income for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $3.0 million.
- Ptc Therapeutics' Operating Income rose 10553.29% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $775.9 million, marking a year-over-year increase of 67747.04%. This contributed to the annual value of -$302.6 million for FY2024, which is 3115.62% up from last year.
- Per Ptc Therapeutics' latest filing, its Operating Income stood at $3.0 million for Q3 2025, which was up 10553.29% from -$35.0 million recorded in Q2 2025.
- Ptc Therapeutics' Operating Income's 5-year high stood at $970.2 million during Q1 2025, with a 5-year trough of -$209.5 million in Q2 2023.
- In the last 5 years, Ptc Therapeutics' Operating Income had a median value of -$86.5 million in 2022 and averaged -$32.9 million.
- In the last 5 years, Ptc Therapeutics' Operating Income crashed by 289018.9% in 2024 and then surged by 223456.76% in 2025.
- Quarter analysis of 5 years shows Ptc Therapeutics' Operating Income stood at -$84.7 million in 2021, then crashed by 136.45% to -$200.3 million in 2022, then soared by 102.91% to $5.8 million in 2023, then plummeted by 2890.19% to -$162.4 million in 2024, then surged by 101.86% to $3.0 million in 2025.
- Its Operating Income stands at $3.0 million for Q3 2025, versus -$35.0 million for Q2 2025 and $970.2 million for Q1 2025.